IO Biotech Announces Achievement Of Significant Phase 3 Clinical Trial Recruitment Milestone
Portfolio Pulse from Happy Mohamed
IO Biotech has reached a significant milestone by randomizing 225 patients in its global Phase 3 clinical trial for IO102-IO103, in combination with Merck's pembrolizumab, for advanced melanoma patients. The trial protocol calls for an interim analysis of overall response rate one year after 225 patients have been enrolled. If positive, this could lead to accelerated approval in the US.
June 14, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Merck's pembrolizumab is being used in combination with IO Biotech's IO102-IO103 in a Phase 3 clinical trial for advanced melanoma patients.
Merck's pembrolizumab is being used in combination with IO Biotech's IO102-IO103 in the Phase 3 clinical trial. While this collaboration is positive for Merck, the impact on its stock price is likely to be limited in the short term, as the trial is still ongoing and the results are not yet known.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
IO Biotech has reached a significant milestone in its Phase 3 clinical trial for IO102-IO103, which could potentially lead to accelerated approval in the US.
IO Biotech reaching the milestone of randomizing 225 patients in its Phase 3 clinical trial for IO102-IO103 is a significant achievement. If the interim analysis of overall response rate is positive, it could lead to accelerated approval in the US, which would be a major catalyst for the company's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100